O11 - Gonorrhoea: epidemiology and vaccine

Moderator(s)

• JD

  Jo-Anne Dillon
• ML

  Maria Luiza Bazzo

Presentations:

• 14:30 – 14:45 CST

  Optimal gonorrhea control through vaccination and screening: a mathematical modeling and cost-effectiveness study
  

  Primary Presenter: Austin M. Williams, PhD (he/him/his) – Centers for Disease Control and Prevention
• 14:45 – 15:00 CST

  Global Surveillance for Antimicrobial Resistant Neisseria gonorrhoeae through the Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2015-2022
  

  Primary Presenter: Rebekah Frankson, MS, MPH – U.S. Centers for Disease Control and Prevention
• 15:00 – 15:15 CST

  Should we use the 4CMenB (Bexsero®) meningitis vaccine to protect men who have sex with men (MSM) in England against gonorrhoea? A model-based analysis of impact and cost-effectiveness.
  

  Primary Presenter: Dariya Nikitin, MSc, MRes – MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London
• 15:15 – 15:30 CST

  Characterisation of meningococcal vaccine-induced antibodies to Neisseria gonorrhoeae
  

  Primary Presenter: Kate L. Seib, BSc (Hons), PhD (she/her/hers) – Institute for Glycomics, Griffith University
• 15:30 – 15:45 CST

  Targeted metagenomic analysis shows distinct Neisseria gonorrhoeae strains at separate anatomical sites occur more commonly than mixed strain infections: implications for surveillance
  

  Primary Presenter: Petra FG Wolffs, PhD (she/her/hers) – Maastricht University Medical Center+

  Co-Author: Brian MJW van der veer – Maastricht University Medical Center+
• 15:45 – 16:00 CST

  Effect of oropharyngeal colonization with Neisseria meningitidis on subsequent risk of gonorrhea
  

  Primary Presenter: Abigail Norris Turner, PhD – Ohio State University